Pilot clinical study on the prevention of complications after lung biopsy by the MIPP kit PNX device.

Percutaneous lung biopsy (PLB) complications lung cancer diagnosis pneumothorax (PNX)

Journal

Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 29 04 2022
accepted: 25 09 2022
entrez: 16 1 2023
pubmed: 17 1 2023
medline: 17 1 2023
Statut: ppublish

Résumé

Pneumothorax (PNX), pulmonary hemorrhage, hemothorax and chest wall hematoma are the most commonly reported complications of percutaneous lung biopsy (PLB). Sealing the biopsy tract with different types of materials is an emerging way to prevent PLB complications. To investigate the safety and efficacy of a new device, Minimally Invasive Percutaneous Procedure Kit for Pneumothorax (MIPP-Kit PNX), when used in association with a resorbable bio-compatible glue in the prevention of PLB complications. A prospective, multicenter, open-label, single-arm study was performed to evaluate the complication rate after glue administration by the new investigational device during PLBs. Fourty-three patients were enrolled after informed consent signature (40 underwent PLB, while three were screening failures). Only 3 patients (7.5%, 95% CI: 0.0-15.7%) developed complications within 48 h after glue injection during PLB: two developed minor pneumothoraces and one a pulmonary hemorrhage. No patients who showed procedural complications before glue administration were reported with any recurrent or new complications after glue administration. In comparison with the data reported in the literature, this trial results support the safe and effective use of the MIPP kit PNX in the prevention of PLB complications. These promising preliminary results warrant further confirmation in larger clinical trials. ClinicalTrials.gov identifier: NCT04071509.

Sections du résumé

Background UNASSIGNED
Pneumothorax (PNX), pulmonary hemorrhage, hemothorax and chest wall hematoma are the most commonly reported complications of percutaneous lung biopsy (PLB). Sealing the biopsy tract with different types of materials is an emerging way to prevent PLB complications.
Methods UNASSIGNED
To investigate the safety and efficacy of a new device, Minimally Invasive Percutaneous Procedure Kit for Pneumothorax (MIPP-Kit PNX), when used in association with a resorbable bio-compatible glue in the prevention of PLB complications. A prospective, multicenter, open-label, single-arm study was performed to evaluate the complication rate after glue administration by the new investigational device during PLBs.
Results UNASSIGNED
Fourty-three patients were enrolled after informed consent signature (40 underwent PLB, while three were screening failures). Only 3 patients (7.5%, 95% CI: 0.0-15.7%) developed complications within 48 h after glue injection during PLB: two developed minor pneumothoraces and one a pulmonary hemorrhage. No patients who showed procedural complications before glue administration were reported with any recurrent or new complications after glue administration.
Conclusions UNASSIGNED
In comparison with the data reported in the literature, this trial results support the safe and effective use of the MIPP kit PNX in the prevention of PLB complications. These promising preliminary results warrant further confirmation in larger clinical trials.
Trial Registration UNASSIGNED
ClinicalTrials.gov identifier: NCT04071509.

Identifiants

pubmed: 36644169
doi: 10.21037/tcr-22-1203
pii: tcr-11-12-4338
pmc: PMC9834579
doi:

Banques de données

ClinicalTrials.gov
['NCT04071509']

Types de publication

Journal Article

Langues

eng

Pagination

4338-4348

Commentaires et corrections

Type : CommentIn

Informations de copyright

2022 Translational Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-1203/coif). PLC has been VP Clinical Operations at Betaglue after the study started until its completion. AA has been CEO/CMO at Betaglue for the entire duration of the study. The other authors have no conflicts of interest to declare.

Références

Cardiovasc Intervent Radiol. 1995 Nov-Dec;18(6):378-82
pubmed: 8591624
Acta Radiol. 2009 Dec;50(10):1126-33
pubmed: 19922309
Semin Intervent Radiol. 2006 Jun;23(2):188-93
pubmed: 21326762
Eur Radiol. 2004 Jul;14(7):1234-40
pubmed: 14963689
J Neurosurg. 2019 Nov 15;:1-11
pubmed: 31731262
Urology. 2006 Apr;67(4):697-700; discussion 700
pubmed: 16566976
J Cancer Res Ther. 2019;15(4):755-759
pubmed: 31436228
J Gastrointest Surg. 2008 May;12(5):882-90
pubmed: 18273671
J Thorac Dis. 2015 Sep;7(9):E341-3
pubmed: 26543626
J Thorac Cardiovasc Surg. 2010 Jul;140(1):32-8
pubmed: 20620377
Insights Imaging. 2017 Aug;8(4):419-428
pubmed: 28639114
Radiology. 1991 Nov;181(2):385-7
pubmed: 1924776
Eur Radiol. 2008 Jul;18(7):1356-63
pubmed: 18351356
AJR Am J Roentgenol. 2006 Oct;187(4):926-32
pubmed: 16985136
J Vasc Interv Radiol. 2014 Aug;25(8):1209-17
pubmed: 24854390
Radiology. 1999 Jan;210(1):59-64
pubmed: 9885587
Pneumologie. 2012 Jul;66(7):432-6
pubmed: 22782457
Surg Obes Relat Dis. 2010 Sep-Oct;6(5):498-501
pubmed: 20176513
Australas Radiol. 2006 Oct;50(5):435-41
pubmed: 16981939
J Vasc Interv Radiol. 2010 Aug;21(8):1235-43.e1-3
pubmed: 20656223
J Thorac Dis. 2017 Mar;9(3):568-576
pubmed: 28449464
J Vasc Interv Radiol. 2010 Jul;21(7):969-75
pubmed: 20304676
AJR Am J Roentgenol. 2010 Mar;194(3):809-14
pubmed: 20173164
Clin Radiol. 2000 Apr;55(4):281-7
pubmed: 10767187
Clin Lung Cancer. 2017 Jan;18(1):e27-e34
pubmed: 27530054
Wien Klin Wochenschr. 2011 Feb;123(3-4):79-82
pubmed: 21327675
Infect Agent Cancer. 2014 Nov 24;9(1):39
pubmed: 25489337
Quant Imaging Med Surg. 2020 May;10(5):1008-1020
pubmed: 32489925
Cardiovasc Intervent Radiol. 2017 Feb;40(2):270-276
pubmed: 27826786
Eur J Radiol. 2014 Apr;83(4):720-5
pubmed: 24534120
J Cardiothorac Surg. 2016 Oct 21;11(1):149
pubmed: 27769306
Clin Radiol. 2015 Nov;70(11):1192-7
pubmed: 26175218
Int J Surg Case Rep. 2016;23:33-5
pubmed: 27085105
Eur Radiol. 2017 Jan;27(1):138-148
pubmed: 27108299
Eur J Radiol. 2012 May;81(5):1029-33
pubmed: 21752567
Cureus. 2019 Jun 2;11(6):e4802
pubmed: 31396470
J Thorac Imaging. 2014 Nov;29(6):344-9
pubmed: 25314026
Infect Agent Cancer. 2015 Apr 10;10:11
pubmed: 25897320

Auteurs

Cosmo Damiano Gadaleta (CD)

Interventional Oncology and Integrated Medicine Department, Istituto Tumori Giovanni Paolo II, Bari, Italy.

Roberto Iezzi (R)

Diagnostic and General Interventional Radiology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Alessandro Tanzilli (A)

Diagnostic and General Interventional Radiology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Giovanni Puppini (G)

Radiology Department, Verona University Hospital, Verona, Italy.

Pier Luigi Carriero (PL)

Betaglue Technologies SpA, Milan, Italy.

Antonino Amato (A)

Betaglue Technologies SpA, Milan, Italy.

Classifications MeSH